Table of Contents Author Guidelines Submit a Manuscript
Pain Research and Management
Volume 2016, Article ID 9703036, 6 pages
http://dx.doi.org/10.1155/2016/9703036
Clinical Study

Feasibility of Topical Applications of Natural High-Concentration Capsaicinoid Solutions in Patients with Peripheral Neuropathic Pain: A Retrospective Analysis

1Department of Anesthesiology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
2Institute of NeuroScience, Cliniques Universitaires Saint-Luc, Brussels, Belgium
3Louvain Drug Research Institute, Cliniques Universitaires Saint-Luc, Brussels, Belgium
4Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium

Received 11 April 2016; Revised 23 November 2016; Accepted 8 December 2016

Academic Editor: Yelena Granovsky

Copyright © 2016 Fanny Bauchy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Baron, A. Binder, and G. Wasner, “Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment,” The Lancet Neurology, vol. 9, no. 8, pp. 807–819, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. O. Van Hecke, S. K. Austin, R. A. Khan, B. H. Smith, and N. Torrance, “Neuropathic pain in the general population: a systematic review of epidemiological studies,” Pain, vol. 155, no. 4, pp. 654–662, 2014. View at Google Scholar
  3. N. Attal, “Neuropathic pain: mechanisms, therapeutic approach, and interpretation of clinical trials,” CONTINUUM Lifelong Learning in Neurology, vol. 18, no. 1, pp. 161–175, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. A. B. O'Connor and R. H. Dworkin, “Treatment of neuropathic pain: an overview of recent guidelines,” American Journal of Medicine, vol. 122, no. 10, pp. S22–S32, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Horváth, M. Boros, T. Bagoly et al., “Analgesic topical capsaicinoid therapy increases somatostatin-like immunoreactivity in the human plasma,” Neuropeptides, vol. 48, no. 6, pp. 371–378, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Maihofner and M.-L. Heskamp, “Prospective, non-interventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1044 patients with peripheral neuropathic pain: first results of the QUEPP study,” Current Medical Research and Opinion, vol. 29, no. 6, pp. 673–683, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Schumacher, “TRP channels in pain and inflammation: therapeutic opportunities,” Pain Practice, vol. 10, pp. 185–200, 2010. View at Google Scholar
  8. X.-J. Luo, J. Peng, and Y.-J. Li, “Recent advances in the study on capsaicinoids and capsinoids,” European Journal of Pharmacology, vol. 650, no. 1, pp. 1–7, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. J. F. Peppin and M. Pappagallo, “Capsaicinoids in the treatment of neuropathic pain: a review,” Therapeutic Advances in Neurological Disorders, vol. 7, no. 1, pp. 22–32, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. D. N. Cortright and A. Szallasi, “TRP channels and pain,” Current Pharmaceutical Design, vol. 15, no. 15, pp. 1736–1749, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Spicarova and J. Palecek, “The role of spinal cord vanilloid (TRPV1) receptors in pain modulation,” Physiological Research, vol. 57, supplement 3, pp. S69–S77, 2008. View at Google Scholar · View at Scopus
  12. H. Knotkova, M. Pappagallo, and A. Szallasi, “Capsaicin (TRPV1 agonist) therapy for pain relief: farewell or revival?” Clinical Journal of Pain, vol. 24, no. 2, pp. 142–154, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. A. B. Malmberg, A. P. Mizisin, N. A. Calcutt, T. Von Stein, W. R. Robbins, and K. R. Bley, “Reduced heat sensitivity and epidermal nerve fiber immunostaining following single applications of a high-concentration capsaicin patch,” Pain, vol. 111, no. 3, pp. 360–367, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Winter, S. Bevan, and E. A. Campbell, “Capsaicin and pain mechanisms,” British Journal of Anaesthesia, vol. 75, no. 2, pp. 157–168, 1995. View at Publisher · View at Google Scholar · View at Scopus
  15. P. L. McCormack, “Capsaicin dermal patch: in non-diabetic peripheral neuropathic pain,” Drugs, vol. 70, no. 14, pp. 1831–1842, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. G. A. Irving, M. M. Backonja, E. Dunteman et al., “A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia,” Pain Medicine, vol. 12, no. 1, pp. 99–109, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Backonja, M. S. Wallace, E. R. Blonsky et al., “NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study,” The Lancet Neurology, vol. 7, no. 12, pp. 1106–1112, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. D. M. Simpson, S. Gazda, S. Brown et al., “Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain,” Journal of Pain and Symptom Management, vol. 39, no. 6, pp. 1053–1064, 2010. View at Google Scholar
  19. D. B. Clifford, D. M. Simpson, S. Brown et al., “A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful hiv-associated distal sensory polyneuropathy,” Journal of Acquired Immune Deficiency Syndromes, vol. 59, no. 2, pp. 126–133, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. R.-D. Treede, T. S. Jensen, J. N. Campbell et al., “Neuropathic pain: redefinition and a grading system for clinical and research purposes,” Neurology, vol. 70, no. 18, pp. 1630–1635, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. EDQM, The European Pharmacopea, EDQM, Strasbourg, France, 8th edition, 2014.
  22. D. Bouhassira, N. Attal, H. Alchaar et al., “Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4),” Pain, vol. 114, no. 1-2, pp. 29–36, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. O. van Hecke, P. R. Kamerman, N. Attal et al., “Neuropathic pain phenotyping by international consensus (NeuroPPIC) for genetic studies: a NeuPSIG systematic review, Delphi survey, and expert panel recommendations,” Pain, vol. 156, no. 11, pp. 2337–2353, 2015. View at Publisher · View at Google Scholar
  24. Astellas Pharma, Qutenza 179 Mg Cutaneous Patch, EMC, 2014, https://www.medicines.org.uk/emc/medicine/23156.
  25. AFT Pharmaceuticals, Zostrix HP, Capsaicin USP 0.075% w/w Topical Cream, 2011, http://www.medsafe.govt.nz/profs/datasheet/z/ZostrixHPCr.pdf.